<DOC>
	<DOC>NCT01284660</DOC>
	<brief_summary>The purpose of this study is to assess effects of Docosahexaenoic Acid (DHA) as an add-on novel supplement on quality of life, cognitive function, craving and psychosocial factors in heavy cigarette smokers. In humans, no previous randomized, double blind controlled study has been conducted to evaluate these effects. The aim of the study is to 1. Test Docosahexaenoic Acid (DHA) beneficial effects on objective clinical indicators of cognitive function (choice reaction time, decision making, impulsivity, facial recognition) in smokers 2. Improvement of quality of life, cigarette craving, psychosocial factors and self-perceptions in smokers treated with DHA supplement</brief_summary>
	<brief_title>Docosahexaenoic Acid (DHA) Effects on Cognitive Function, Craving and Psychosocial Factors in Heavy Cigarette Smokers</brief_title>
	<detailed_description />
	<criteria>Nicotine dependence Smoked at least 10 cigarettes per day for the past 12 months and not interested in quitting Serious kidney, lun, neurological and cardiovascular diseases Suicide risk, acute psychosis, severe depression, organic brain syndromes Dependence on psychoactive substances other than nicotine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>